Novel Genetic Mutation that Causes the Most Common form of Eye Cancer Discovered

An international, multi-center study has revealed the discovery of a novel oncogene that is associated with uveal melanoma, the most common form of eye cancer. Researchers have isolated an oncogene called GNA11 and have found that it is present in more than 40 percent of tumor samples taken from patients with uveal melanoma.

Wednesday, November 17, 2010
Samuel Danishefsky
Memorial Sloan Kettering Enters Agreement to Develop New Cancer Drug

As part of a commitment to seek new and better treatments for cancer patients, Memorial Sloan Kettering Cancer Center and Bristol-Myers Squibb are collaborating to bring a potential new cancer drug called iso-fludelone, or KOS-1803, into clinical trials.

Friday, October 1, 2010
Alexander Rudensky
An Interview With Alexander Rudensky

A member of the Sloan Kettering Institute’s Immunology Program and a Howard Hughes Medical Institute investigator, Alexander Rudensky is fascinated by how a specific type of white blood cells called regulatory T cells regulates our immune system.

Friday, October 1, 2010
Study Answers Important Question about Using Carbon Nanotubes in Medicine

A multicenter study led by Memorial Sloan Kettering researchers has answered an important question about the safety of using carbon nanotubes in medicine.

Friday, October 1, 2010
Pictured: Eric C. Holland
Researchers Discover Genetic Changes That Make Some Forms of Brain Cancer More Aggressive Than Others

A multi-institutional team led by investigators from Memorial Sloan Kettering Cancer Center has published a study that provides new insight into genetic changes that make some forms of glioblastoma, the most common type of primary brain cancer, more aggressive than others and explains why they may not respond to certain therapies.

Friday, October 1, 2010
2010 Shaps Scholars

Four summer students — Jeannie Camarillo, Emily Grzybowski, Nathaniel Kim, and Daniel Triner — were named 2010 Rubin and Sarah Shaps Scholars.

Wednesday, September 1, 2010
A Decade of Leadership

Harold Varmus became President and Chief Executive Officer of Memorial Sloan Kettering Cancer Center on January 1, 2000. He ended his decade-long tenure on July 1, 2010. And on July 12, 2010, Dr. Varmus took up a new role as Director of the National Cancer Institute.

Thursday, July 1, 2010
Ingo Mellinghoff
Researchers Uncover Molecular Interactions in Common Form of Brain Cancer

A multicenter team led by Memorial Sloan Kettering neurologist and researcher Ingo K. Mellinghoff has uncovered the relationship between two proteins that play a critical role in glioblastoma, the most common form of brain cancer.

Thursday, July 1, 2010
Inherited Mutations May Point to an Aggressive Form of Prostate Cancer

A team of Memorial Sloan Kettering researchers reports that prostate cancer often takes an aggressive course in patients who have inherited mutations in the genes BRCA1 or BRCA2.

Thursday, July 1, 2010
Boris Bastian Named Chair of the Department of Pathology

Physician-scientist Boris C. Bastian joined Memorial Sloan Kettering as Attending Physician and Chair of the Department of Pathology on April 1.

Thursday, July 1, 2010